Cadila Healthcare Receives USFDA Nod for Albendazole Tablets to Treat Tapeworm Infections

Cadila Healthcare’s group company Zydus Cadila said it has received the final approval from the US Food and Drug Administration to market Albendazole tablets, USP 200 mg. The drug will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to treat certain tapeworm infections (such as neurocysticercosis and hydatid disease). The group also received a tentative approval for Pregabalin capsules in the strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.  The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. Pregabalin is used to help control certain kinds of seizures, painful nerve diseases and fibromyalgia. The Cadila group now has 239 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY04. – Money Control